— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
— Revenue plunged by 39% to $230,000 versus $50,000 expected. The top line was hurt by nil contract revenue.
— Research and development expenses soared by 59% due to the manufacturing of voclosporin for commercial and investigational use. It also includes costs related to the Aurora 2 extension study and other expenses.
— As looking forward to results from the Aurora Phase 3 trial for kidney inflammation lupus nephritis by the end of this year, the company has been preparing for success by continuing to strengthen the Board.
— Looking ahead to 2020, and assuming positive results, Aurinia plans on submitting an NDA in the first half of 2020 and projects a commercial launch of voclosporin in early 2021 as a potential first-line treatment for lupus nephritis.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on